CAS: 55981-09-4; 2-((5-Nitrothiazol-2-yl)Carbamoyl)Phenyl Acetate

上下游产品

CAS号121-66-4 2-氨基-5-硝基噻唑 | CAS号5538-51-2 邻乙酰水杨酰氯 | CAS号130234-70-7 2-hydroxy-N-(1,...

2-[(2-Acetyloxybenzoyl)Amino]-1,3-Thiazole-5-Carboxylic Acid置于nitronium Tetrafluoborate,Silver Carbonate体系中,用 N,N-二甲基乙酰胺 作为反应溶剂,化学反应 12.0H,以71%的收率获得产物硝唑尼特
参考文献:银(i)促进的ipso羧酸由四氟硼酸硝的-Nitration
标题:银(i)促进的ipso羧酸由四氟硼酸硝的-Nitration
摘要:已经描述了使用四氟硼酸硝基鎓和碳酸银在二甲基乙酰胺中将一系列脂族和芳族羧酸区域选择性硝化为它们相应的硝基化合物的新颖而有效的方法.据信这种转化是通过烷基-银或芳基-银中间体进行的,该中间体随后与硝鎓离子反应形成硝基物质.温和的反应条件下,宽范围的官能团的耐受性,并形成仅的本位相比,硝基烷基和硝基芳烃的合成公知的方法时-Nitrated产品是这种方法的关键特征.
DOI:10.1021/acs.Joc.5B02133

专利信息

专利号:US-11672829-B2
优先权日:2015-09-10
标 题:Genetically engineered coronavirus-specific effector cells for in situ synthesis of antiviral proteins
发明人：BHATNAGAR PARIJAT; SSEMADAALI MARVIN A
权利人:STANFORD RES INST INT
摘要:An example genetically engineered effector cell comprises an exogenous polynucleotide sequence that includes a receptor element, an actuator element, and an effector element. The receptor element encodes a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain operably linked to a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen binding domain recognizes an antigen on a surface of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-infected cell. The actuator element encodes a transcription factor binding site that upregulates synthesis of an antiviral protein. The effector element encodes the antiviral protein operably linked to a signal peptide, wherein, in response to the antigen binding domain of the CAR binding to the antigen of SARS-CoV-2-infected cell, the engineered effector cell is configured to activate and, to synthesize and secrete the antiviral protein.

专利号:US-9573939-B2
优先权日:2011-09-08
标题:Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
发明人：MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; DANG QUN
权利人:MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; DANG QUN; MERCK SHARP & DOHME; MSD ITALIA SRL
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-8021645-B2
优先权日:2006-12-13
标 题 :Synthesis of human secretory IgA and IgM and the formation of a medicament therefrom
发明人：SIMON MICHAEL R; CHERVIN STEPHANIE M; BROWN STEPHEN C
权利人:SIMON MICHAEL R; CHERVIN STEPHANIE M; BROWN STEPHEN C
摘要:A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

专利号:US-7794721-B2
优先权日:2006-12-13
标题 :Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
发明人：SIMON MICHAEL R
权利人:SIMON MICHAEL R
摘要:A composition for treating a subject is provided. The composition includes a pentameric secretory IgM therapeutic. Formulating agents are mixed with the pentameric secretory IgM to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of pentameric IgM with secretory component to form a pentameric secretory IgM therapeutic. The pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

专利号:US-9382288-B2
优先权日:2010-10-06
标题 :Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action
发明人：BECKER KATJA; KRIEG REIMAR; SCHÖNECKER BRUNO
权利人:BECKER KATJA; KRIEG REIMAR; SCHÖNECKER BRUNO; UNIV GIESSEN JUSTUS LIEBIG
摘要:The present invention relates to compounds derived from steroids of the general formula (I) n nwherein L represents a linker and R # represents a steroid residue, the use of compounds of the general formula (I) in medicine and for the prophylaxis and/or the treatment of infectious diseases. Furthermore described are pharmaceutical compositions containing at least one compound of the general formula (I). A further aspect of the invention relates to the synthesis of said compounds of the general formula (I).

专利号:US-7597891-B2
优先权日:2006-12-13
标题:Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
发明人：SIMON MICHAEL R
权利人:SIMON MICHAEL R
摘要:A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided wherein dimeric or polymeric IgA is modified with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.